Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
-
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
-
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
-
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
-
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
-
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
-
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
-
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia